This requires determining the structure and form of the processed antigen of the B-cell-recognized MHC molecule as the basis for in vitro processing and loading and applying it in the form of a vaccine to cancer patients to induce adaptive immunity in B cells [123]. The gene discussed is HLA-C; the disease is cancer.